Targeted therapy with sunitinib or sorafenib combining with gemcitabine plus cisplatin in the treatment of metastatic collecting duct carcinoma of the kidney.
Phase of Trial: Phase IV
Latest Information Update: 22 Apr 2016
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary) ; Cisplatin; Gemcitabine
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 May 2012 Actual end date (14 Aug 2010) added as reported by Chinese Clinical Trial Register.
- 15 Nov 2011 New trial record